RA
GNCA

Royce & Associates’s Genocea Biosciences, Inc. GNCA Stock Holding History

Royce & Associates’s Portfolio GNCA Stock Details GNCA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-6,575
Closed -$277K – 1147
2015
Q4 		$277K Buy
+6,575
New +$313K ﹤0.01% 1060

Other funds holding GNCA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
PVMCV
Polaris Venture Management Co V Boston, Massachusetts $14.1M AUM 121.41% 1-Year Est. Return
NC
Northpointe Capital Bloomfield Hills, Michigan $258M AUM 1.97% 1-Year Est. Return
AIC
AWM Investment Company New York $1.15B AUM 201.65% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Axa
Axa Paris, France $91.9M AUM 27.41% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

Royce & Associates's GNCA Position: Q1 2016 in Review

Royce & Associates sold out of Genocea Biosciences, Inc. (GNCA) in Q1 2016, closing a stake of 6,575 shares — an estimated $277K sold.

Royce & Associates first reported a position in GNCA in Q4 2015 and held it in 1 quarter. The position peaked at $277K in Q4 2015. 59 funds tracked by Wall St. Rank hold GNCA as of Q1 2016.

  • Royce & Associates reported no remaining Genocea Biosciences, Inc. position as of Q1 2016 after selling out during the quarter.
  • Royce & Associates sold 6,575 Genocea Biosciences, Inc. shares in Q1 2016, an estimated $277K.
  • Royce & Associates first reported a position in Genocea Biosciences, Inc. in Q4 2015 and held it in 1 quarter.
  • Royce & Associates's Genocea Biosciences, Inc. position peaked at $277K in Q4 2015.
  • 59 funds tracked by Wall St. Rank held Genocea Biosciences, Inc. as of Q1 2016.

Based on Royce & Associates's 13F filing for Q1 2016, filed 11 May 2016.